DNA Damage Is a Potential Marker for TP53 Mutation in Colorectal Carcinogenesis

被引:0
|
作者
Scalise J.R. [1 ]
Poças R.C.G. [1 ]
Caneloi T.P. [2 ]
Lopes C.O. [2 ]
Kanno D.T. [2 ]
Marques M.G. [2 ]
Valdivia J.C.M. [2 ]
Maximo F.R. [2 ]
Pereira J.A. [3 ]
Ribeiro M.L. [1 ]
Priolli D.G. [1 ,4 ]
机构
[1] Postgraduate Programme Strictu Senso in Health Science, Sao Francisco University Medical School, Sao Paulo
[2] Scientific Initiation Student, Scientific Initiation Programme, Sao Francisco University Medical School, Sao Paulo
[3] Department of Pathology, Sao Francisco University Medical School, Sao Paulo
[4] Rua São Vicente 614. Jardim Paulista, Atibaia, CEP: 12947-390, SP
基金
巴西圣保罗研究基金会;
关键词
Adenocarcinoma; Adenoma; DNA damage; Immunohistochemistry; Tumor suppressor protein p53;
D O I
10.1007/s12029-016-9846-0
中图分类号
学科分类号
摘要
Purpose: The ability to measure oxidative DNA damage in a tissue allows establishment of the relationship between DNA damage and mutations in normal and neoplastic cells. It is well known that TP53 is a key inhibitor of tumor development and preserves the genome integrity in each cell. The aim of the present study was to investigate the relationship between DNA damage and TP53 mutation in colorectal adenoma and adenocarcinoma, and the value of DNA damage as potential marker of TP53 mutation in non-tumor tissues adjacent to colon malignant lesions. Methods: Tissue samples were obtained by colonoscopy from patients with adenoma and/or adenocarcinoma and from healthy volunteers. Diagnosis was defined by histopathology. Immunohistochemistry with computer-assisted image analysis was performed to quantify TP53 mutation. Oxidative DNA damage was determined by comet assay. Statistical analyses were performed with 5 % of significance level. Results: The TP53 level was higher in non-tumor tissues from tumor patients than in normal tissues from healthy volunteers (p = 0.01). Likewise, higher TP53 levels were observed in tumor tissues compared with the non-tumor tissues (p = 0.00). Oxidative DNA damage levels were higher in tumor tissues than in non-tumor tissues (p = 0.00). The amount of TP53 (p = 0.00) and oxidative DNA damage (p = 0.00) in normal and tumor tissue was related. The relationship between oxidative DNA damage and TP53 mutation was demonstrated in all samples (p = 0.00). Conclusion: Oxidative DNA damage is an intervening variable for TP53 mutation in colorectal adenoma-carcinoma. Our data suggests that oxidative DNA damage is a potential marker of TP53 mutation in colorectal carcinogenesis. © 2016, Springer Science+Business Media New York.
引用
收藏
页码:409 / 416
页数:7
相关论文
共 50 条
  • [21] TP53 as a biomarker of cytogenetic damage
    Hendrikse, A
    Hunter, A
    Blekkenhorst, G
    HEALTH PHYSICS, 2000, 78 (06): : 753 - 753
  • [22] Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer
    Kim, Ji-Yeon
    Park, Kyunghee
    Jung, Hae Hyun
    Lee, Eunjin
    Cho, Eun Yoon
    Lee, Kwang Hee
    Bae, Soo Youn
    Lee, Se Kyung
    Kim, Seok Won
    Lee, Jeong Eon
    Nam, Seok Jin
    Ahn, Jin Seok
    Im, Young-Hyuck
    Park, Yeon Hee
    CANCER RESEARCH AND TREATMENT, 2016, 48 (04): : 1338 - 1350
  • [23] TP53 Status Predicts DNA Damage Response Pathways in Breast
    Pfister, N. T.
    Regunath, K.
    Connolly, E. P.
    Prives, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E518 - E518
  • [24] Alterations of the TP53 Gene in Gastric and Esophageal Carcinogenesis
    Bellini, Marilanda Ferreira
    Targa Cadamuro, Aline Cristina
    Succi, Maysa
    Proenca, Marcela Alcantara
    Silva, Ana Elizabete
    JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2012,
  • [25] Mutation of the TP53 Gene in Placental Chorangiomatosis
    Luo, Ying
    FETAL AND PEDIATRIC PATHOLOGY, 2023, 42 (03) : 400 - 409
  • [26] Clinical significance of TP53 mutation in myeloma
    Chng, W. J.
    Price-Troska, T.
    Gonzalez-Paz, N.
    Van Wier, S.
    Jacobus, S.
    Blood, E.
    Henderson, K.
    Oken, M.
    Van Ness, B.
    Greipp, P.
    Rajkumar, S. V.
    Fonseca, R.
    LEUKEMIA, 2007, 21 (03) : 582 - 584
  • [27] TP53 mutation in mucinous carcinoma of the breast
    Di Palma, S
    Lavarino, C
    Oggionni, M
    Pilotti, S
    HISTOPATHOLOGY, 1999, 34 (06) : 559 - 560
  • [28] TP53 mutation is an independent prognostic marker for good outcome in basal breast cancer
    Kang, S. H.
    Choi, J. E.
    Park, J. Y.
    Son, G. T.
    Lee, J. H.
    Bae, Y. K.
    Lee, S. J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S193 - S194
  • [29] Sarcomas in TP53 germline mutation carriers
    Ognjanovic, Simona
    Olivier, Magali
    Bergemann, Tracy L.
    Hainaut, Pierre
    CANCER RESEARCH, 2011, 71
  • [30] TP53 mutation is rare in primary myelofibrosis
    Greaves, Wesley O.
    Verma, Shalini
    Bisrat, Tigist
    Strati, Paolo
    Rahimi, Hamed
    Paladugu, Abhaya V.
    Luthra, Rajyalakshmi
    Patel, Keyur P.
    Medeiros, L. Jeff Rey
    Yao, Hui
    Pierce, Sherry
    Bueso-Ramos, Carlos E.
    Verstovsek, Srdan
    LEUKEMIA & LYMPHOMA, 2013, 54 (07) : 1552 - 1552